Melanoma and Immunotherapy

Lex Eggermont; D Schadendorf

doi:10.1016/j.hoc.2009.03.009

Melanoma and Immunotherapy

Lex Eggermont, D Schadendorf

Surgery

Research output: Contribution to journal › Article › Academic › peer-review

41 Citations (Scopus)

Abstract

About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

Original language	Undefined/Unknown
Pages (from-to)	547-+
Journal	Hematology-Oncology Clinics of North America
Volume	23
Issue number	3
DOIs	https://doi.org/10.1016/j.hoc.2009.03.009
Publication status	Published - 2009

Access to Document

10.1016/j.hoc.2009.03.009

http://hdl.handle.net/1765/16295

Cite this

@article{318326febeb6490eae90dce45e3b8668,

title = "Melanoma and Immunotherapy",

abstract = "About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.",

author = "Lex Eggermont and D Schadendorf",

year = "2009",

doi = "10.1016/j.hoc.2009.03.009",

language = "Undefined/Unknown",

volume = "23",

pages = "547--+",

journal = "Hematology-Oncology Clinics of North America",

issn = "0889-8588",

number = "3",

}

TY - JOUR

T1 - Melanoma and Immunotherapy

AU - Eggermont, Lex

AU - Schadendorf, D

PY - 2009

Y1 - 2009

N2 - About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

AB - About 20% of all primary melanomas will spread. The likelihood of metastatic behavior correlates with prognostic factors such as tumor thickness, mitotic index, presence of ulceration, lymphocyte infiltration, age, gender, and anatomic site. Immunotherapies are developed for melanoma patients in stage IV who have distant metastases and in stage II to III patients in the adjuvant micrometastatic setting, where only a fraction of patients have widespread (microscopic) disease.

U2 - 10.1016/j.hoc.2009.03.009

DO - 10.1016/j.hoc.2009.03.009

M3 - Article

SN - 0889-8588

VL - 23

SP - 547-+

JO - Hematology-Oncology Clinics of North America

JF - Hematology-Oncology Clinics of North America

IS - 3

ER -